The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders

Antibodies to SOXB1 proteins in patients with paraneoplastic disorders are associated with small-cell lung cancer (SCLC), particularly in Lambert-Eaton myasthenic syndrome (LEMS). We aimed to establish if SOX2 antibodies could be used to identify SCLC and other tumours found in a range of paraneopla...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neuroimmunology 2019-01, Vol.326, p.14-18
Main Authors:	Maddison, Paul, Titulaer, Maarten J., Verschuuren, Jan J., Gozzard, Paul, Lang, Bethan, Irani, Sarosh R., Sabater, Lidia, Graus, Francesc, Murray, Andrea, Chapman, Caroline J.
Format:	Article
Language:	eng
Subjects:	Adolescent Adult Aged Aged, 80 and over Antibodies Autoantibodies - blood Biomarkers, Tumor - blood Female Humans Lambert-Eaton myasthenic syndrome Lung Neoplasms - blood Lung Neoplasms - diagnosis Lung Neoplasms - immunology Male Middle Aged Paraneoplastic Paraneoplastic Syndromes - blood Paraneoplastic Syndromes - etiology Paraneoplastic Syndromes - immunology Sensitivity and Specificity Small Cell Lung Carcinoma - blood Small Cell Lung Carcinoma - diagnosis Small Cell Lung Carcinoma - immunology Small-cell lung cancer SOX2 SOXB1 Transcription Factors - immunology Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Antibodies to SOXB1 proteins in patients with paraneoplastic disorders are associated with small-cell lung cancer (SCLC), particularly in Lambert-Eaton myasthenic syndrome (LEMS). We aimed to establish if SOX2 antibodies could be used to identify SCLC and other tumours found in a range of paraneoplastic disorders and controls. SOX2 antibodies were detectable in 61% of patients with LEMS-SCLC, and in other paraneoplastic disorders, such as opsoclonus-myoclonus and paraneoplastic cerebellar degeneration, only when there was an underlying SCLC. SOX2 antibodies are specific (>90%) markers for SCLC, but are rarely found in patients with other tumours, whether neurological symptoms are present or not. •SOX2 antibodies only seen in small-cell lung cancer (SCLC), not other tumours•61% of patients with Lambert-Eaton syndrome and SCLC have SOX2 antibodies.•Patients with paraneoplastic disorders only have SOX2 antibodies if SCLC is present.
ISSN:	0165-5728 1872-8421